Impact of potential inappropriate NSAIDs use in XXXX .

@entity1 @entity137 @entity354 @entity158 @entity1118 @entity734 @entity7634
@entity158 remains one of the main reasons for medical consultation worldwide: moderate- to severe-intensity @entity158 occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives. Nonsteroidal anti-inflammatory drugs (NSAIDs) are not recommended for long-term use and a careful surveillance to monitor for @entity137 and efficacy is critical. This study aims to assess: 1) the pattern of use of NSAIDs and opioids in a population covered by a cloud-based pharmacovigilance surveillance system; and 2) potential inappropriate use. A retrospective 18-months systematic analysis on @entity1 ' @entity158 treatment was performed. The primary endpoint was evaluating the prevalence of NSAIDs and opioids use and the duration of therapy regimen. The secondary endpoint was to investigate the prevalence of NSAIDs taken for >21 consecutive days concomitant with drugs for peptic ulcer and @entity354 ( @entity354 ) or antiplatelet drugs. The yearly cost for individual users of concomitant NSAIDs for more than 21 consecutive days and of @entity354 medications has been estimated. A total of 3,050 subjects with @entity1118 were enrolled; 97% of them took NSAIDs for >21 consecutive days; about one-fourth of these users also received drugs for peptic ulcer and @entity354 (Anatomical Therapeutic Chemical code A02B). The yearly cost foran individual who uses NSAIDs for >21 consecutive days as well as concomitant @entity354 medications is 61.23 @entity7634 . In total, 238 subjects (8%) using NSAIDs for >21 days also received one antiplatelet agent. About 11% of subjects received opioids at least once and only 2% of them carried on the therapy for more than 90 consecutive days. In evaluating the escalation in dosage as a proxy of @entity734 risk, this study shows no dosage escalation in our cohort of @entity1118 population - that is to say we show no risk of @entity734 .
